Press release
Myelofibrosis Clinical Trial Drug Development Pipeline Expands with Contributions from 50+ Key Companies | DelveInsight
(Albany, US) September 30, 2026 - DelveInsight's "Myelofibrosis Pipeline Insights 2026" report provides comprehensive insights about 50+ companies and 55+ pipeline drugs in the Myelofibrosis pipeline landscape. It covers the Myelofibrosis pipeline drug profiles, including clinical and nonclinical-stage products. It also covers the Myelofibrosis therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Download DelveInsight's comprehensive Myelofibrosis Pipeline Report to explore emerging therapies @ https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Key Takeaways from the Myelofibrosis Pipeline Report
* On September 29, 2026- Novartis Pharmaceuticals initiated a phase 3 study for each participant is composed of several distinct periods: a screening period, a study treatment period, and a post-treatment follow-up phase. The purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have not previously received Janus kinase (JAK) inhibitor therapy.
* On September 23, 2026- Disc Medicine Inc . conducted a phase 1b/2a open-label study will evaluate the safety, tolerability, pharmacokinetics, pharmacodynamics, and clinical activity of DISC-0974 as well as categorize the effects on hematologic response in participants with myelofibrosis or myelodysplastic syndrome and anemia.
* On September 23, 2026- Sumitomo Pharma America Inc . highlighted a Phase 1/2 study dose-escalation, open-label trial to assess safety, tolerability, pharmacokinetics and pharmacodynamics of nuvisertib (TP-3654) in patients with intermediate or high-risk primary or secondary MF.
* DelveInsight's Myelofibrosis pipeline report depicts a robust space with 35+ active players working to develop 40+ pipeline therapies for Myelofibrosis treatment.
* The leading Myelofibrosis Companies such as PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
* Promising Myelofibrosis Therapies such as Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib , and others.
Access DelveInsight's in-depth Myelofibrosis Pipeline Analysis for a closer look at promising breakthroughs @ Myelofibrosis Clinical Trials and Studies [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myelofibrosis Overview
Myelofibrosis is a chronic blood cancer in which clonal abnormalities in hematopoietic stem cells drive progressive bone marrow fibrosis, resulting in ineffective blood cell production and clinical features such as anemia, splenomegaly, and fatigue. It is classified as a BCR-ABL1-negative myeloproliferative neoplasm and may arise de novo or evolve from antecedent conditions like polycythemia vera or essential thrombocythemia. The disease is strongly associated with driver mutations in JAK2, CALR, or MPL, which lead to persistent activation of the JAK-STAT signaling pathway and a pro-inflammatory cytokine milieu.
Myelofibrosis Emerging Drugs
* Ropeginterferon alfa-2b: PharmaEssentia Corporation
Ropeginterferon alfa-2b is a long-acting, mono-pegylated interferon designed for sustained activation of interferon signaling with improved tolerability and convenient dosing compared to earlier interferons. It exerts antiproliferative and immunomodulatory effects, helping to suppress malignant hematopoietic clones and restore more normal bone marrow function. The drug is currently being studied in a Phase III clinical trial for the treatment of Myelofibrosis.
* Roginolisib: iOnctura
Roginolisib is an orally available, first-in-class allosteric modulator of PI3K, distinguished by its unique binding mode that alters the protein's 3D conformation and selectively inhibits its activity. By targeting the PI3K isoform commonly dysregulated in cancers and expressed in immunosuppressive cells, it aims to reverse tumor-associated immune suppression while directly inhibing malignant cell proliferation. In myelofibrosis, Roginolisib may help counteract immune-mediated resistance mechanisms that limit current therapies. It is currently being evaluated in a Phase II clinical trial for the treatment of Myelofibrosis.
* RVU120: Ryvu Therapeutics
RVU120 is an oral, selective inhibitor of CDK8 and CDK19, key regulators of transcriptional pathways involved in oncogenesis and inflammation. In Myelofibrosis, it modulates aberrant signaling such as STAT-driven pathways, helping to suppress malignant hematopoietic cell proliferation. The drug has demonstrated potential disease-modifying activity, including reduction of inflammatory cytokines and fibrosis-associated signaling. RVU120 is currently in Phase II of its clinical development, with early studies indicating activity in patients resistant or refractory to JAK inhibitor therapies.
* PRT12396: Prelude Therapeutics
PRT12396 is a mutant-selective JAK2V617F inhibitor being developed for the treatment of patients with certain myeloproliferative neoplasms (MPNs). It has received Investigational New Drug (IND) clearance from the US Food and Drug Administration, enabling clinical evaluation in advanced malignancies, including hematologic cancers. It is currently being evaluated in a Phase I clinical trial for the treatment of Myelofibrosis.
The Myelofibrosis Pipeline report provides insights into
* The report provides detailed insights about companies that are developing therapies for the treatment of Myelofibrosis with aggregate therapies developed by each company for the same.
* It accesses the Different therapeutic candidates segmented into early-stage, mid-stage, and late-stage of development for Myelofibrosis Treatment.
* Myelofibrosis Companies are involved in targeted therapeutics development with respective active and inactive (dormant or discontinued) projects.
* Myelofibrosis Drugs under development based on the stage of development, route of administration, target receptor, monotherapy or combination therapy, a different mechanism of action, and molecular type.
* Detailed analysis of collaborations (company-company collaborations and company-academia collaborations), licensing agreement and financing details for future advancement of the Myelofibrosis market.
Explore DelveInsight's expert-driven report today! @ Myelofibrosis Unmet Needs [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Myelofibrosis Companies
PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
Myelofibrosis pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
* Oral
* Intravenous
* Subcutaneous
* Parenteral
* Topical
Myelofibrosis Products have been categorized under various Molecule types such as
* Recombinant fusion proteins
* Small molecule
* Monoclonal antibody
* Peptide
* Polymer
* Gene therapy
Download DelveInsight's latest report to gain strategic insights into upcoming Myelofibrosis Therapies @ Myelofibrosis Market Drivers and Barriers, and Future Perspectives [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Scope of the Myelofibrosis Pipeline Report
* Coverage- Global
* Myelofibrosis Companies- PharmaEssentia Corporation, iOnctura, Prelude Therapeutics, Cellenkos, Ajax Therapeutics, Eilean Therapeutics, Phoenix Molecular Designs, Ryvu Therapeutics, Disc Medicine, Sumitomo Pharma, CERo Therapeutics, Stemline Therapeutics, Incyte Corporation, Takeda, Syntara Limited, Opna Bio, Epigenetix, Chia Tai Tianqing Pharmaceutical Group Co., Ltd., GluBio Therapeutics, Telios Pharma, Inc. and others.
* Myelofibrosis Therapies- Momelotinib, Luspatercept, Bomedemstat, Pacritinib, RVU120, Ruxolitinib, and others.
* Myelofibrosis Therapeutic Assessment by Product Type: Mono, Combination, Mono/Combination
* Myelofibrosis Therapeutic Assessment by Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
Find out in DelveInsight's exclusive Myelofibrosis Pipeline Report @ Myelofibrosis Emerging Drugs and Major Companies [https://www.delveinsight.com/sample-request/myelofibrosis-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=ypr]
Table of Content
* Introduction
* Executive Summary
* Myelofibrosis: Overview
* Myelofibrosis Pipeline Therapeutics
* Myelofibrosis Therapeutic Assessment
* Myelofibrosis - DelveInsight's Analytical Perspective
* Late Stage Products (Phase III)
* Ropeginterferon alfa-2b: PharmaEssentia Corporation
* Drug profiles in the detailed report.....
* Mid Stage Products (Phase II)
* Roginolisib: iOnctura
* Drug profiles in the detailed report.....
* PRT12396: Prelude Therapeutics
* Drug profiles in the detailed report.....
* Preclinical and Discovery Stage Products
* Drug name: Company name
* Drug profiles in the detailed report.....
* Inactive Products
* Myelofibrosis Key Companies
* Myelofibrosis Key Products
* Myelofibrosis Unmet Needs
* Myelofibrosis Market Drivers and Barriers
* Myelofibrosis Future Perspectives and Conclusion
* Myelofibrosis Analyst Views
* Appendix
About Us
DelveInsight is a leading healthcare-focused market research and consulting firm that provides clients with high-quality market intelligence and analysis to support informed business decisions. With a team of experienced industry experts and a deep understanding of the life sciences and healthcare sectors, we offer customized research solutions and insights to clients across the globe. Connect with us to get high-quality, accurate, and real-time intelligence to stay ahead of the growth curve.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=myelofibrosis-clinical-trial-drug-development-pipeline-expands-with-contributions-from-50-key-companies-delveinsight]
Phone: 09650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/report-store/myelofibrosis-pipeline-insight
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Myelofibrosis Clinical Trial Drug Development Pipeline Expands with Contributions from 50+ Key Companies | DelveInsight here
News-ID: 4649095 • Views: …
More Releases from ABNewswire
San Francisco Speeding Ticket Attorney Adam Cohen Explains Penalties for Driving …
SAN FRANCISCO, CA - September 30, 2026 - Drivers cited for traveling more than 100 miles per hour on a California highway face consequences that reach well beyond an ordinary speeding ticket, including significant fines, DMV points, and potential license suspension. San Francisco speeding ticket attorney Adam Cohen of Ticket Crushers, A Law Corporation (https://www.ticketcrusherslaw.com/traffic-ticket/speeding-tickets/cvc-22348b/) is providing guidance on how California Vehicle Code section 22348(b) works and what options are…
New York DWI Defense Attorney Randall F. Inniss Explains How Licensed Profession …
MIDDLETOWN, NY - September 30, 2026 - Licensed professionals throughout the Hudson Valley face consequences that go far beyond fines and potential jail time when charged with Driving While Intoxicated in New York. New York DWI defense attorney Randall F. Inniss of The Inniss Firm, PLLC (https://www.trooper2lawyer.com/ny-professional-license-dwi-defense/) outlines the licensing board risks, mandatory reporting obligations, and dual-track defense strategy that professionals must pursue from the moment of arrest.
According to New…
Chronic Heart Failure Market Set to Expand as Novel Drug Classes, Label Expansio …
Key Chronic Heart Failure companies such as Novartis, Boehringer Ingelheim, Eli Lilly and Company, Bayer, Cytokinetics, BioCardia, Novo Nordisk, Mesoblast, and others.
(Albany, US) September 30, 2026 - DelveInsight's "Chronic Heart Failure Treatment Market Insights, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of Chronic Heart Failure, historical and forecasted epidemiology, and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and…
PCSK9 Inhibitors Market Set for Expansion as Cardiovascular Disease Burden Rises …
Key PCSK9 Inhibitors companies such as Sanofi, Regeneron Pharmaceuticals, Amgen, Novartis, Alnylam Pharmaceuticals, LIB Therapeutics, AstraZeneca, Ionis Pharmaceuticals, CiVi Biopharma, and others.
(Albany, US) September 30, 2026 - DelveInsight's "PCSK9 Inhibitors Market Insight, Epidemiology, and Market Forecast - 2034" report delivers an in-depth understanding of PCSK9 inhibitors, historical and forecasted epidemiology, the competitive landscape, and market trends across the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and…
More Releases for Myelofibrosis
Myelofibrosis Pipeline Therapeutics Assessment Report 2024 (Updated)
DelveInsight's, "Myelofibrosis Pipeline Insight 2024" report provides comprehensive insights about 35+ companies and 40+ pipeline drugs in Myelofibrosis pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Explore our latest breakthroughs in Myelofibrosis Research. Learn more about our innovative…
Secondary Myelofibrosis Therapeutics Market - Revolutionizing Treatment for Seco …
Newark, New Castle, USA: The "Secondary Myelofibrosis Therapeutics Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Secondary Myelofibrosis Therapeutics Market: https://www.growthplusreports.com/report/secondary-myelofibrosis-therapeutics-market/8885
This latest report researches the industry structure,…
Myelofibrosis Market - Transforming Challenges into Triumphs: Myelofibrosis Mark …
Newark, New Castle, USA: The "Myelofibrosis Market" provides a value chain analysis of revenue for the anticipated period from 2023 to 2031. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors.
Myelofibrosis Market: https://www.growthplusreports.com/report/myelofibrosis-market/8802
This latest report researches the industry structure, sales, revenue, price and…
Secondary Myelofibrosis Therapeutics Market - Unleashing Resilience, Defying Mye …
Newark, New Castle, USA - new report, titled Secondary Myelofibrosis Therapeutics Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Secondary Myelofibrosis Therapeutics market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Secondary Myelofibrosis Therapeutics market. The report offers an overview of…
Chronic Idiopathic Myelofibrosis Market 2022 | Detailed Report
The Chronic Idiopathic Myelofibrosis report understands the current and future competitive scenario across types, countries, and applications.It provides accurate, up-to-date analysis of markets and companies.The report use reliable information and analysis to gain a deeper understanding of the current factors impacting the industry.
The Chronic Idiopathic Myelofibrosis report provides exact and accurate data that helps companies of all sizes to make timely decisions. Furthermore, the report provides robust solutions to customers,…
Myelofibrosis Therapeutics Market Research Report by Valuates Reports
Latest updates on "Myelofibrosis Market"
Primary myelofibrosis is a relatively rare bone marrow cancer. It is currently classified as a myeloproliferative neoplasm, in which the proliferation of an abnormal clone of hematopoietic stem cells in the bone marrow and other sites results in fibrosis, or the replacement of the marrow with scar tissue.
The market report provides the overview of the Myelofibrosis by providing the disease overview, definition, classification, symptoms, etiology, pathophysiology…
